Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/ip-environment-deteriorating-in-india-us-pharma-industry-21760/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/ip-environment-deteriorating-in-india-us-pharma-industry-21760/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/ip-environment-deteriorating-in-india-us-pharma-industry-21760/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/ip-environment-deteriorating-in-india-us-pharma-industry-21760/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f3558c7165c-trace').style.display = (document.getElementById('cakeErr67f3558c7165c-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f3558c7165c-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f3558c7165c-code').style.display = (document.getElementById('cakeErr67f3558c7165c-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f3558c7165c-context').style.display = (document.getElementById('cakeErr67f3558c7165c-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f3558c7165c-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f3558c7165c-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 21613,
		&#039;title&#039; =&gt; &#039;IP environment deteriorating in India: US pharma industry&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-PTI
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;India however maintained that the India Patent Act was in accordance with the TRIPS Agreement &amp;amp; the Paris Convention&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The US pharma industry has expressed concern over deteriorating intellectual property environment in India, alleging that patent rights in the country are unreasonably denied.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;PhRMA remains concerned about the deteriorating intellectual property environment in India,&amp;quot; Mark Grayson, PhRMA spokesman told PTI.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The remarks by PhRMA or Pharmaceutical Research and Manufacturers of America, representing America&#039;s leading biopharmaceutical researchers and biotechnology companies, comes days after the India&#039;s Ambassador to the US, Nirupama Rao, wrote to US lawmakers and a Congressional committee held a hearing on the issue.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;We have shared our views about the importance of promoting a policy environment that supports continued research and development of new medicines with Ambassador Rao and other members of the Indian Government,&amp;quot; Grayson said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In a letter to US lawmakers last month, Rao had defended India&#039;s IP policy arguing that India has a well-settled, stable and robust intellectual property regime.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;The three main pillars of this regime are comprehensive laws, detailed rules to back them up, and strong enforcement mechanisms, including for dispute resolution,&amp;quot; she had said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Rao had said of all patents granted for pharmaceutical inventions between 2005 and 2011, more than 85% were owned by foreign companies in India, with US holding 20-30%  share of the patents.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Noting that the provisions of the Compulsory License enshrined in the India Patent Act are in accordance with the provisions of the TRIPs Agreement and the Paris Convention, she had said that through such licensing mechanisms, all governments balance the rights of the patent holder.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Since its inception, Compulsory Licensing has been an integral part of the patent regime of different countries. Globally, 15 different countries, developed and developing alike, have issued more than 35 compulsory licenses. India has issued only one Compulsory License,&amp;quot; Rao said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
However, Rao&#039;s letter has failed to convince the US pharma industry who continues to push the Obama Administration on India&#039;s policies related to the intellectual property regime.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;India&#039;s protectionist and discriminatory policies which exploit U S IP to benefit their own industry requires an equally bold response.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
It is important that we view these actions for what they are, industrialist policies to benefit the competitiveness of India&#039;s own domestic industry,&amp;quot; Roy Waldron, Chief Intellectual Property Officer with Pfizer, told lawmakers last week.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;India&#039;s actions to undermine the incentives needed to make investment to develop new medicines, a hostile environment to IP will have a devastating impact on R&amp;amp;D investment in both the US and India and cause significant harm for US jobs and economic growth,&amp;quot; he said.
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Business Standard, 2 July, 2013, http://www.business-standard.com/article/economy-policy/ip-environment-deteriorating-in-india-us-pharma-industry-113070200127_1.html&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;ip-environment-deteriorating-in-india-us-pharma-industry-21760&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 21760,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 21613,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | IP environment deteriorating in India: US pharma industry&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;medicines,patents,generic drugs,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-PTI



India however maintained that the India Patent Act was in accordance with the TRIPS Agreement &amp;amp; the Paris Convention


The US pharma industry has expressed concern over deteriorating intellectual property environment in India, alleging that patent rights in the country are...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-PTI&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;India however maintained that the India Patent Act was in accordance with the TRIPS Agreement &amp;amp; the Paris Convention&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The US pharma industry has expressed concern over deteriorating intellectual property environment in India, alleging that patent rights in the country are unreasonably denied.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;PhRMA remains concerned about the deteriorating intellectual property environment in India,&amp;quot; Mark Grayson, PhRMA spokesman told PTI.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The remarks by PhRMA or Pharmaceutical Research and Manufacturers of America, representing America&#039;s leading biopharmaceutical researchers and biotechnology companies, comes days after the India&#039;s Ambassador to the US, Nirupama Rao, wrote to US lawmakers and a Congressional committee held a hearing on the issue.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;We have shared our views about the importance of promoting a policy environment that supports continued research and development of new medicines with Ambassador Rao and other members of the Indian Government,&amp;quot; Grayson said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In a letter to US lawmakers last month, Rao had defended India&#039;s IP policy arguing that India has a well-settled, stable and robust intellectual property regime.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;The three main pillars of this regime are comprehensive laws, detailed rules to back them up, and strong enforcement mechanisms, including for dispute resolution,&amp;quot; she had said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Rao had said of all patents granted for pharmaceutical inventions between 2005 and 2011, more than 85% were owned by foreign companies in India, with US holding 20-30%  share of the patents.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Noting that the provisions of the Compulsory License enshrined in the India Patent Act are in accordance with the provisions of the TRIPs Agreement and the Paris Convention, she had said that through such licensing mechanisms, all governments balance the rights of the patent holder.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Since its inception, Compulsory Licensing has been an integral part of the patent regime of different countries. Globally, 15 different countries, developed and developing alike, have issued more than 35 compulsory licenses. India has issued only one Compulsory License,&amp;quot; Rao said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;However, Rao&#039;s letter has failed to convince the US pharma industry who continues to push the Obama Administration on India&#039;s policies related to the intellectual property regime.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;India&#039;s protectionist and discriminatory policies which exploit U S IP to benefit their own industry requires an equally bold response.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;It is important that we view these actions for what they are, industrialist policies to benefit the competitiveness of India&#039;s own domestic industry,&amp;quot; Roy Waldron, Chief Intellectual Property Officer with Pfizer, told lawmakers last week.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;India&#039;s actions to undermine the incentives needed to make investment to develop new medicines, a hostile environment to IP will have a devastating impact on R&amp;amp;D investment in both the US and India and cause significant harm for US jobs and economic growth,&amp;quot; he said.&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 21613,
	&#039;title&#039; =&gt; &#039;IP environment deteriorating in India: US pharma industry&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-PTI
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;India however maintained that the India Patent Act was in accordance with the TRIPS Agreement &amp;amp; the Paris Convention&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The US pharma industry has expressed concern over deteriorating intellectual property environment in India, alleging that patent rights in the country are unreasonably denied.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;PhRMA remains concerned about the deteriorating intellectual property environment in India,&amp;quot; Mark Grayson, PhRMA spokesman told PTI.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The remarks by PhRMA or Pharmaceutical Research and Manufacturers of America, representing America&#039;s leading biopharmaceutical researchers and biotechnology companies, comes days after the India&#039;s Ambassador to the US, Nirupama Rao, wrote to US lawmakers and a Congressional committee held a hearing on the issue.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;We have shared our views about the importance of promoting a policy environment that supports continued research and development of new medicines with Ambassador Rao and other members of the Indian Government,&amp;quot; Grayson said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In a letter to US lawmakers last month, Rao had defended India&#039;s IP policy arguing that India has a well-settled, stable and robust intellectual property regime.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;The three main pillars of this regime are comprehensive laws, detailed rules to back them up, and strong enforcement mechanisms, including for dispute resolution,&amp;quot; she had said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Rao had said of all patents granted for pharmaceutical inventions between 2005 and 2011, more than 85% were owned by foreign companies in India, with US holding 20-30%  share of the patents.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Noting that the provisions of the Compulsory License enshrined in the India Patent Act are in accordance with the provisions of the TRIPs Agreement and the Paris Convention, she had said that through such licensing mechanisms, all governments balance the rights of the patent holder.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Since its inception, Compulsory Licensing has been an integral part of the patent regime of different countries. Globally, 15 different countries, developed and developing alike, have issued more than 35 compulsory licenses. India has issued only one Compulsory License,&amp;quot; Rao said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
However, Rao&#039;s letter has failed to convince the US pharma industry who continues to push the Obama Administration on India&#039;s policies related to the intellectual property regime.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;India&#039;s protectionist and discriminatory policies which exploit U S IP to benefit their own industry requires an equally bold response.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
It is important that we view these actions for what they are, industrialist policies to benefit the competitiveness of India&#039;s own domestic industry,&amp;quot; Roy Waldron, Chief Intellectual Property Officer with Pfizer, told lawmakers last week.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;India&#039;s actions to undermine the incentives needed to make investment to develop new medicines, a hostile environment to IP will have a devastating impact on R&amp;amp;D investment in both the US and India and cause significant harm for US jobs and economic growth,&amp;quot; he said.
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Business Standard, 2 July, 2013, http://www.business-standard.com/article/economy-policy/ip-environment-deteriorating-in-india-us-pharma-industry-113070200127_1.html&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;ip-environment-deteriorating-in-india-us-pharma-industry-21760&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 21760,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 21613
$metaTitle = &#039;LATEST NEWS UPDATES | IP environment deteriorating in India: US pharma industry&#039;
$metaKeywords = &#039;medicines,patents,generic drugs,Health&#039;
$metaDesc = &#039;
-PTI



India however maintained that the India Patent Act was in accordance with the TRIPS Agreement &amp;amp; the Paris Convention


The US pharma industry has expressed concern over deteriorating intellectual property environment in India, alleging that patent rights in the country are...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-PTI&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;India however maintained that the India Patent Act was in accordance with the TRIPS Agreement &amp;amp; the Paris Convention&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The US pharma industry has expressed concern over deteriorating intellectual property environment in India, alleging that patent rights in the country are unreasonably denied.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;PhRMA remains concerned about the deteriorating intellectual property environment in India,&amp;quot; Mark Grayson, PhRMA spokesman told PTI.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The remarks by PhRMA or Pharmaceutical Research and Manufacturers of America, representing America&#039;s leading biopharmaceutical researchers and biotechnology companies, comes days after the India&#039;s Ambassador to the US, Nirupama Rao, wrote to US lawmakers and a Congressional committee held a hearing on the issue.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;We have shared our views about the importance of promoting a policy environment that supports continued research and development of new medicines with Ambassador Rao and other members of the Indian Government,&amp;quot; Grayson said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In a letter to US lawmakers last month, Rao had defended India&#039;s IP policy arguing that India has a well-settled, stable and robust intellectual property regime.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;The three main pillars of this regime are comprehensive laws, detailed rules to back them up, and strong enforcement mechanisms, including for dispute resolution,&amp;quot; she had said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Rao had said of all patents granted for pharmaceutical inventions between 2005 and 2011, more than 85% were owned by foreign companies in India, with US holding 20-30%  share of the patents.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Noting that the provisions of the Compulsory License enshrined in the India Patent Act are in accordance with the provisions of the TRIPs Agreement and the Paris Convention, she had said that through such licensing mechanisms, all governments balance the rights of the patent holder.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Since its inception, Compulsory Licensing has been an integral part of the patent regime of different countries. Globally, 15 different countries, developed and developing alike, have issued more than 35 compulsory licenses. India has issued only one Compulsory License,&amp;quot; Rao said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;However, Rao&#039;s letter has failed to convince the US pharma industry who continues to push the Obama Administration on India&#039;s policies related to the intellectual property regime.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;India&#039;s protectionist and discriminatory policies which exploit U S IP to benefit their own industry requires an equally bold response.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;It is important that we view these actions for what they are, industrialist policies to benefit the competitiveness of India&#039;s own domestic industry,&amp;quot; Roy Waldron, Chief Intellectual Property Officer with Pfizer, told lawmakers last week.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;India&#039;s actions to undermine the incentives needed to make investment to develop new medicines, a hostile environment to IP will have a devastating impact on R&amp;amp;D investment in both the US and India and cause significant harm for US jobs and economic growth,&amp;quot; he said.&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/ip-environment-deteriorating-in-india-us-pharma-industry-21760.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | IP environment deteriorating in India: US pharma industry | Im4change.org</title>
    <meta name="description" content="
-PTI



India however maintained that the India Patent Act was in accordance with the TRIPS Agreement &amp; the Paris Convention


The US pharma industry has expressed concern over deteriorating intellectual property environment in India, alleging that patent rights in the country are..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>IP environment deteriorating in India: US pharma industry</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-PTI</div><p align="justify"><br /><em>India however maintained that the India Patent Act was in accordance with the TRIPS Agreement &amp; the Paris Convention</em></p><p align="justify">The US pharma industry has expressed concern over deteriorating intellectual property environment in India, alleging that patent rights in the country are unreasonably denied.</p><p align="justify">&quot;PhRMA remains concerned about the deteriorating intellectual property environment in India,&quot; Mark Grayson, PhRMA spokesman told PTI.</p><p align="justify">The remarks by PhRMA or Pharmaceutical Research and Manufacturers of America, representing America's leading biopharmaceutical researchers and biotechnology companies, comes days after the India's Ambassador to the US, Nirupama Rao, wrote to US lawmakers and a Congressional committee held a hearing on the issue.</p><p align="justify">&quot;We have shared our views about the importance of promoting a policy environment that supports continued research and development of new medicines with Ambassador Rao and other members of the Indian Government,&quot; Grayson said.</p><p align="justify">In a letter to US lawmakers last month, Rao had defended India's IP policy arguing that India has a well-settled, stable and robust intellectual property regime.</p><p align="justify">&quot;The three main pillars of this regime are comprehensive laws, detailed rules to back them up, and strong enforcement mechanisms, including for dispute resolution,&quot; she had said.</p><p align="justify">Rao had said of all patents granted for pharmaceutical inventions between 2005 and 2011, more than 85% were owned by foreign companies in India, with US holding 20-30%  share of the patents.</p><p align="justify">Noting that the provisions of the Compulsory License enshrined in the India Patent Act are in accordance with the provisions of the TRIPs Agreement and the Paris Convention, she had said that through such licensing mechanisms, all governments balance the rights of the patent holder.</p><p align="justify">&quot;Since its inception, Compulsory Licensing has been an integral part of the patent regime of different countries. Globally, 15 different countries, developed and developing alike, have issued more than 35 compulsory licenses. India has issued only one Compulsory License,&quot; Rao said.</p><p align="justify">However, Rao's letter has failed to convince the US pharma industry who continues to push the Obama Administration on India's policies related to the intellectual property regime.</p><p align="justify">&quot;India's protectionist and discriminatory policies which exploit U S IP to benefit their own industry requires an equally bold response.</p><p align="justify">It is important that we view these actions for what they are, industrialist policies to benefit the competitiveness of India's own domestic industry,&quot; Roy Waldron, Chief Intellectual Property Officer with Pfizer, told lawmakers last week.</p><p align="justify">&quot;India's actions to undermine the incentives needed to make investment to develop new medicines, a hostile environment to IP will have a devastating impact on R&amp;D investment in both the US and India and cause significant harm for US jobs and economic growth,&quot; he said.</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f3558c7165c-trace').style.display = (document.getElementById('cakeErr67f3558c7165c-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f3558c7165c-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f3558c7165c-code').style.display = (document.getElementById('cakeErr67f3558c7165c-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f3558c7165c-context').style.display = (document.getElementById('cakeErr67f3558c7165c-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f3558c7165c-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f3558c7165c-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 21613,
		&#039;title&#039; =&gt; &#039;IP environment deteriorating in India: US pharma industry&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-PTI
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;India however maintained that the India Patent Act was in accordance with the TRIPS Agreement &amp;amp; the Paris Convention&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The US pharma industry has expressed concern over deteriorating intellectual property environment in India, alleging that patent rights in the country are unreasonably denied.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;PhRMA remains concerned about the deteriorating intellectual property environment in India,&amp;quot; Mark Grayson, PhRMA spokesman told PTI.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The remarks by PhRMA or Pharmaceutical Research and Manufacturers of America, representing America&#039;s leading biopharmaceutical researchers and biotechnology companies, comes days after the India&#039;s Ambassador to the US, Nirupama Rao, wrote to US lawmakers and a Congressional committee held a hearing on the issue.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;We have shared our views about the importance of promoting a policy environment that supports continued research and development of new medicines with Ambassador Rao and other members of the Indian Government,&amp;quot; Grayson said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In a letter to US lawmakers last month, Rao had defended India&#039;s IP policy arguing that India has a well-settled, stable and robust intellectual property regime.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;The three main pillars of this regime are comprehensive laws, detailed rules to back them up, and strong enforcement mechanisms, including for dispute resolution,&amp;quot; she had said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Rao had said of all patents granted for pharmaceutical inventions between 2005 and 2011, more than 85% were owned by foreign companies in India, with US holding 20-30%  share of the patents.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Noting that the provisions of the Compulsory License enshrined in the India Patent Act are in accordance with the provisions of the TRIPs Agreement and the Paris Convention, she had said that through such licensing mechanisms, all governments balance the rights of the patent holder.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Since its inception, Compulsory Licensing has been an integral part of the patent regime of different countries. Globally, 15 different countries, developed and developing alike, have issued more than 35 compulsory licenses. India has issued only one Compulsory License,&amp;quot; Rao said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
However, Rao&#039;s letter has failed to convince the US pharma industry who continues to push the Obama Administration on India&#039;s policies related to the intellectual property regime.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;India&#039;s protectionist and discriminatory policies which exploit U S IP to benefit their own industry requires an equally bold response.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
It is important that we view these actions for what they are, industrialist policies to benefit the competitiveness of India&#039;s own domestic industry,&amp;quot; Roy Waldron, Chief Intellectual Property Officer with Pfizer, told lawmakers last week.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;India&#039;s actions to undermine the incentives needed to make investment to develop new medicines, a hostile environment to IP will have a devastating impact on R&amp;amp;D investment in both the US and India and cause significant harm for US jobs and economic growth,&amp;quot; he said.
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Business Standard, 2 July, 2013, http://www.business-standard.com/article/economy-policy/ip-environment-deteriorating-in-india-us-pharma-industry-113070200127_1.html&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;ip-environment-deteriorating-in-india-us-pharma-industry-21760&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 21760,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 21613,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | IP environment deteriorating in India: US pharma industry&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;medicines,patents,generic drugs,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-PTI



India however maintained that the India Patent Act was in accordance with the TRIPS Agreement &amp;amp; the Paris Convention


The US pharma industry has expressed concern over deteriorating intellectual property environment in India, alleging that patent rights in the country are...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-PTI&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;India however maintained that the India Patent Act was in accordance with the TRIPS Agreement &amp;amp; the Paris Convention&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The US pharma industry has expressed concern over deteriorating intellectual property environment in India, alleging that patent rights in the country are unreasonably denied.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;PhRMA remains concerned about the deteriorating intellectual property environment in India,&amp;quot; Mark Grayson, PhRMA spokesman told PTI.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The remarks by PhRMA or Pharmaceutical Research and Manufacturers of America, representing America&#039;s leading biopharmaceutical researchers and biotechnology companies, comes days after the India&#039;s Ambassador to the US, Nirupama Rao, wrote to US lawmakers and a Congressional committee held a hearing on the issue.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;We have shared our views about the importance of promoting a policy environment that supports continued research and development of new medicines with Ambassador Rao and other members of the Indian Government,&amp;quot; Grayson said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In a letter to US lawmakers last month, Rao had defended India&#039;s IP policy arguing that India has a well-settled, stable and robust intellectual property regime.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;The three main pillars of this regime are comprehensive laws, detailed rules to back them up, and strong enforcement mechanisms, including for dispute resolution,&amp;quot; she had said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Rao had said of all patents granted for pharmaceutical inventions between 2005 and 2011, more than 85% were owned by foreign companies in India, with US holding 20-30%  share of the patents.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Noting that the provisions of the Compulsory License enshrined in the India Patent Act are in accordance with the provisions of the TRIPs Agreement and the Paris Convention, she had said that through such licensing mechanisms, all governments balance the rights of the patent holder.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Since its inception, Compulsory Licensing has been an integral part of the patent regime of different countries. Globally, 15 different countries, developed and developing alike, have issued more than 35 compulsory licenses. India has issued only one Compulsory License,&amp;quot; Rao said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;However, Rao&#039;s letter has failed to convince the US pharma industry who continues to push the Obama Administration on India&#039;s policies related to the intellectual property regime.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;India&#039;s protectionist and discriminatory policies which exploit U S IP to benefit their own industry requires an equally bold response.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;It is important that we view these actions for what they are, industrialist policies to benefit the competitiveness of India&#039;s own domestic industry,&amp;quot; Roy Waldron, Chief Intellectual Property Officer with Pfizer, told lawmakers last week.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;India&#039;s actions to undermine the incentives needed to make investment to develop new medicines, a hostile environment to IP will have a devastating impact on R&amp;amp;D investment in both the US and India and cause significant harm for US jobs and economic growth,&amp;quot; he said.&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 21613,
	&#039;title&#039; =&gt; &#039;IP environment deteriorating in India: US pharma industry&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-PTI
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;India however maintained that the India Patent Act was in accordance with the TRIPS Agreement &amp;amp; the Paris Convention&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The US pharma industry has expressed concern over deteriorating intellectual property environment in India, alleging that patent rights in the country are unreasonably denied.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;PhRMA remains concerned about the deteriorating intellectual property environment in India,&amp;quot; Mark Grayson, PhRMA spokesman told PTI.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The remarks by PhRMA or Pharmaceutical Research and Manufacturers of America, representing America&#039;s leading biopharmaceutical researchers and biotechnology companies, comes days after the India&#039;s Ambassador to the US, Nirupama Rao, wrote to US lawmakers and a Congressional committee held a hearing on the issue.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;We have shared our views about the importance of promoting a policy environment that supports continued research and development of new medicines with Ambassador Rao and other members of the Indian Government,&amp;quot; Grayson said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In a letter to US lawmakers last month, Rao had defended India&#039;s IP policy arguing that India has a well-settled, stable and robust intellectual property regime.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;The three main pillars of this regime are comprehensive laws, detailed rules to back them up, and strong enforcement mechanisms, including for dispute resolution,&amp;quot; she had said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Rao had said of all patents granted for pharmaceutical inventions between 2005 and 2011, more than 85% were owned by foreign companies in India, with US holding 20-30%  share of the patents.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Noting that the provisions of the Compulsory License enshrined in the India Patent Act are in accordance with the provisions of the TRIPs Agreement and the Paris Convention, she had said that through such licensing mechanisms, all governments balance the rights of the patent holder.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Since its inception, Compulsory Licensing has been an integral part of the patent regime of different countries. Globally, 15 different countries, developed and developing alike, have issued more than 35 compulsory licenses. India has issued only one Compulsory License,&amp;quot; Rao said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
However, Rao&#039;s letter has failed to convince the US pharma industry who continues to push the Obama Administration on India&#039;s policies related to the intellectual property regime.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;India&#039;s protectionist and discriminatory policies which exploit U S IP to benefit their own industry requires an equally bold response.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
It is important that we view these actions for what they are, industrialist policies to benefit the competitiveness of India&#039;s own domestic industry,&amp;quot; Roy Waldron, Chief Intellectual Property Officer with Pfizer, told lawmakers last week.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;India&#039;s actions to undermine the incentives needed to make investment to develop new medicines, a hostile environment to IP will have a devastating impact on R&amp;amp;D investment in both the US and India and cause significant harm for US jobs and economic growth,&amp;quot; he said.
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Business Standard, 2 July, 2013, http://www.business-standard.com/article/economy-policy/ip-environment-deteriorating-in-india-us-pharma-industry-113070200127_1.html&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;ip-environment-deteriorating-in-india-us-pharma-industry-21760&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 21760,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 21613
$metaTitle = &#039;LATEST NEWS UPDATES | IP environment deteriorating in India: US pharma industry&#039;
$metaKeywords = &#039;medicines,patents,generic drugs,Health&#039;
$metaDesc = &#039;
-PTI



India however maintained that the India Patent Act was in accordance with the TRIPS Agreement &amp;amp; the Paris Convention


The US pharma industry has expressed concern over deteriorating intellectual property environment in India, alleging that patent rights in the country are...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-PTI&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;India however maintained that the India Patent Act was in accordance with the TRIPS Agreement &amp;amp; the Paris Convention&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The US pharma industry has expressed concern over deteriorating intellectual property environment in India, alleging that patent rights in the country are unreasonably denied.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;PhRMA remains concerned about the deteriorating intellectual property environment in India,&amp;quot; Mark Grayson, PhRMA spokesman told PTI.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The remarks by PhRMA or Pharmaceutical Research and Manufacturers of America, representing America&#039;s leading biopharmaceutical researchers and biotechnology companies, comes days after the India&#039;s Ambassador to the US, Nirupama Rao, wrote to US lawmakers and a Congressional committee held a hearing on the issue.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;We have shared our views about the importance of promoting a policy environment that supports continued research and development of new medicines with Ambassador Rao and other members of the Indian Government,&amp;quot; Grayson said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In a letter to US lawmakers last month, Rao had defended India&#039;s IP policy arguing that India has a well-settled, stable and robust intellectual property regime.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;The three main pillars of this regime are comprehensive laws, detailed rules to back them up, and strong enforcement mechanisms, including for dispute resolution,&amp;quot; she had said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Rao had said of all patents granted for pharmaceutical inventions between 2005 and 2011, more than 85% were owned by foreign companies in India, with US holding 20-30%  share of the patents.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Noting that the provisions of the Compulsory License enshrined in the India Patent Act are in accordance with the provisions of the TRIPs Agreement and the Paris Convention, she had said that through such licensing mechanisms, all governments balance the rights of the patent holder.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Since its inception, Compulsory Licensing has been an integral part of the patent regime of different countries. Globally, 15 different countries, developed and developing alike, have issued more than 35 compulsory licenses. India has issued only one Compulsory License,&amp;quot; Rao said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;However, Rao&#039;s letter has failed to convince the US pharma industry who continues to push the Obama Administration on India&#039;s policies related to the intellectual property regime.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;India&#039;s protectionist and discriminatory policies which exploit U S IP to benefit their own industry requires an equally bold response.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;It is important that we view these actions for what they are, industrialist policies to benefit the competitiveness of India&#039;s own domestic industry,&amp;quot; Roy Waldron, Chief Intellectual Property Officer with Pfizer, told lawmakers last week.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;India&#039;s actions to undermine the incentives needed to make investment to develop new medicines, a hostile environment to IP will have a devastating impact on R&amp;amp;D investment in both the US and India and cause significant harm for US jobs and economic growth,&amp;quot; he said.&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/ip-environment-deteriorating-in-india-us-pharma-industry-21760.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | IP environment deteriorating in India: US pharma industry | Im4change.org</title>
    <meta name="description" content="
-PTI



India however maintained that the India Patent Act was in accordance with the TRIPS Agreement &amp; the Paris Convention


The US pharma industry has expressed concern over deteriorating intellectual property environment in India, alleging that patent rights in the country are..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>IP environment deteriorating in India: US pharma industry</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-PTI</div><p align="justify"><br /><em>India however maintained that the India Patent Act was in accordance with the TRIPS Agreement &amp; the Paris Convention</em></p><p align="justify">The US pharma industry has expressed concern over deteriorating intellectual property environment in India, alleging that patent rights in the country are unreasonably denied.</p><p align="justify">&quot;PhRMA remains concerned about the deteriorating intellectual property environment in India,&quot; Mark Grayson, PhRMA spokesman told PTI.</p><p align="justify">The remarks by PhRMA or Pharmaceutical Research and Manufacturers of America, representing America's leading biopharmaceutical researchers and biotechnology companies, comes days after the India's Ambassador to the US, Nirupama Rao, wrote to US lawmakers and a Congressional committee held a hearing on the issue.</p><p align="justify">&quot;We have shared our views about the importance of promoting a policy environment that supports continued research and development of new medicines with Ambassador Rao and other members of the Indian Government,&quot; Grayson said.</p><p align="justify">In a letter to US lawmakers last month, Rao had defended India's IP policy arguing that India has a well-settled, stable and robust intellectual property regime.</p><p align="justify">&quot;The three main pillars of this regime are comprehensive laws, detailed rules to back them up, and strong enforcement mechanisms, including for dispute resolution,&quot; she had said.</p><p align="justify">Rao had said of all patents granted for pharmaceutical inventions between 2005 and 2011, more than 85% were owned by foreign companies in India, with US holding 20-30%  share of the patents.</p><p align="justify">Noting that the provisions of the Compulsory License enshrined in the India Patent Act are in accordance with the provisions of the TRIPs Agreement and the Paris Convention, she had said that through such licensing mechanisms, all governments balance the rights of the patent holder.</p><p align="justify">&quot;Since its inception, Compulsory Licensing has been an integral part of the patent regime of different countries. Globally, 15 different countries, developed and developing alike, have issued more than 35 compulsory licenses. India has issued only one Compulsory License,&quot; Rao said.</p><p align="justify">However, Rao's letter has failed to convince the US pharma industry who continues to push the Obama Administration on India's policies related to the intellectual property regime.</p><p align="justify">&quot;India's protectionist and discriminatory policies which exploit U S IP to benefit their own industry requires an equally bold response.</p><p align="justify">It is important that we view these actions for what they are, industrialist policies to benefit the competitiveness of India's own domestic industry,&quot; Roy Waldron, Chief Intellectual Property Officer with Pfizer, told lawmakers last week.</p><p align="justify">&quot;India's actions to undermine the incentives needed to make investment to develop new medicines, a hostile environment to IP will have a devastating impact on R&amp;D investment in both the US and India and cause significant harm for US jobs and economic growth,&quot; he said.</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f3558c7165c-trace').style.display = (document.getElementById('cakeErr67f3558c7165c-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f3558c7165c-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f3558c7165c-code').style.display = (document.getElementById('cakeErr67f3558c7165c-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f3558c7165c-context').style.display = (document.getElementById('cakeErr67f3558c7165c-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f3558c7165c-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f3558c7165c-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 21613,
		&#039;title&#039; =&gt; &#039;IP environment deteriorating in India: US pharma industry&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-PTI
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;India however maintained that the India Patent Act was in accordance with the TRIPS Agreement &amp;amp; the Paris Convention&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The US pharma industry has expressed concern over deteriorating intellectual property environment in India, alleging that patent rights in the country are unreasonably denied.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;PhRMA remains concerned about the deteriorating intellectual property environment in India,&amp;quot; Mark Grayson, PhRMA spokesman told PTI.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The remarks by PhRMA or Pharmaceutical Research and Manufacturers of America, representing America&#039;s leading biopharmaceutical researchers and biotechnology companies, comes days after the India&#039;s Ambassador to the US, Nirupama Rao, wrote to US lawmakers and a Congressional committee held a hearing on the issue.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;We have shared our views about the importance of promoting a policy environment that supports continued research and development of new medicines with Ambassador Rao and other members of the Indian Government,&amp;quot; Grayson said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In a letter to US lawmakers last month, Rao had defended India&#039;s IP policy arguing that India has a well-settled, stable and robust intellectual property regime.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;The three main pillars of this regime are comprehensive laws, detailed rules to back them up, and strong enforcement mechanisms, including for dispute resolution,&amp;quot; she had said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Rao had said of all patents granted for pharmaceutical inventions between 2005 and 2011, more than 85% were owned by foreign companies in India, with US holding 20-30%  share of the patents.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Noting that the provisions of the Compulsory License enshrined in the India Patent Act are in accordance with the provisions of the TRIPs Agreement and the Paris Convention, she had said that through such licensing mechanisms, all governments balance the rights of the patent holder.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Since its inception, Compulsory Licensing has been an integral part of the patent regime of different countries. Globally, 15 different countries, developed and developing alike, have issued more than 35 compulsory licenses. India has issued only one Compulsory License,&amp;quot; Rao said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
However, Rao&#039;s letter has failed to convince the US pharma industry who continues to push the Obama Administration on India&#039;s policies related to the intellectual property regime.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;India&#039;s protectionist and discriminatory policies which exploit U S IP to benefit their own industry requires an equally bold response.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
It is important that we view these actions for what they are, industrialist policies to benefit the competitiveness of India&#039;s own domestic industry,&amp;quot; Roy Waldron, Chief Intellectual Property Officer with Pfizer, told lawmakers last week.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;India&#039;s actions to undermine the incentives needed to make investment to develop new medicines, a hostile environment to IP will have a devastating impact on R&amp;amp;D investment in both the US and India and cause significant harm for US jobs and economic growth,&amp;quot; he said.
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Business Standard, 2 July, 2013, http://www.business-standard.com/article/economy-policy/ip-environment-deteriorating-in-india-us-pharma-industry-113070200127_1.html&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;ip-environment-deteriorating-in-india-us-pharma-industry-21760&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 21760,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 21613,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | IP environment deteriorating in India: US pharma industry&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;medicines,patents,generic drugs,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-PTI



India however maintained that the India Patent Act was in accordance with the TRIPS Agreement &amp;amp; the Paris Convention


The US pharma industry has expressed concern over deteriorating intellectual property environment in India, alleging that patent rights in the country are...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-PTI&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;India however maintained that the India Patent Act was in accordance with the TRIPS Agreement &amp;amp; the Paris Convention&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The US pharma industry has expressed concern over deteriorating intellectual property environment in India, alleging that patent rights in the country are unreasonably denied.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;PhRMA remains concerned about the deteriorating intellectual property environment in India,&amp;quot; Mark Grayson, PhRMA spokesman told PTI.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The remarks by PhRMA or Pharmaceutical Research and Manufacturers of America, representing America&#039;s leading biopharmaceutical researchers and biotechnology companies, comes days after the India&#039;s Ambassador to the US, Nirupama Rao, wrote to US lawmakers and a Congressional committee held a hearing on the issue.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;We have shared our views about the importance of promoting a policy environment that supports continued research and development of new medicines with Ambassador Rao and other members of the Indian Government,&amp;quot; Grayson said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In a letter to US lawmakers last month, Rao had defended India&#039;s IP policy arguing that India has a well-settled, stable and robust intellectual property regime.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;The three main pillars of this regime are comprehensive laws, detailed rules to back them up, and strong enforcement mechanisms, including for dispute resolution,&amp;quot; she had said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Rao had said of all patents granted for pharmaceutical inventions between 2005 and 2011, more than 85% were owned by foreign companies in India, with US holding 20-30%  share of the patents.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Noting that the provisions of the Compulsory License enshrined in the India Patent Act are in accordance with the provisions of the TRIPs Agreement and the Paris Convention, she had said that through such licensing mechanisms, all governments balance the rights of the patent holder.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Since its inception, Compulsory Licensing has been an integral part of the patent regime of different countries. Globally, 15 different countries, developed and developing alike, have issued more than 35 compulsory licenses. India has issued only one Compulsory License,&amp;quot; Rao said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;However, Rao&#039;s letter has failed to convince the US pharma industry who continues to push the Obama Administration on India&#039;s policies related to the intellectual property regime.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;India&#039;s protectionist and discriminatory policies which exploit U S IP to benefit their own industry requires an equally bold response.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;It is important that we view these actions for what they are, industrialist policies to benefit the competitiveness of India&#039;s own domestic industry,&amp;quot; Roy Waldron, Chief Intellectual Property Officer with Pfizer, told lawmakers last week.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;India&#039;s actions to undermine the incentives needed to make investment to develop new medicines, a hostile environment to IP will have a devastating impact on R&amp;amp;D investment in both the US and India and cause significant harm for US jobs and economic growth,&amp;quot; he said.&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 21613,
	&#039;title&#039; =&gt; &#039;IP environment deteriorating in India: US pharma industry&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-PTI
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;India however maintained that the India Patent Act was in accordance with the TRIPS Agreement &amp;amp; the Paris Convention&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The US pharma industry has expressed concern over deteriorating intellectual property environment in India, alleging that patent rights in the country are unreasonably denied.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;PhRMA remains concerned about the deteriorating intellectual property environment in India,&amp;quot; Mark Grayson, PhRMA spokesman told PTI.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The remarks by PhRMA or Pharmaceutical Research and Manufacturers of America, representing America&#039;s leading biopharmaceutical researchers and biotechnology companies, comes days after the India&#039;s Ambassador to the US, Nirupama Rao, wrote to US lawmakers and a Congressional committee held a hearing on the issue.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;We have shared our views about the importance of promoting a policy environment that supports continued research and development of new medicines with Ambassador Rao and other members of the Indian Government,&amp;quot; Grayson said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In a letter to US lawmakers last month, Rao had defended India&#039;s IP policy arguing that India has a well-settled, stable and robust intellectual property regime.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;The three main pillars of this regime are comprehensive laws, detailed rules to back them up, and strong enforcement mechanisms, including for dispute resolution,&amp;quot; she had said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Rao had said of all patents granted for pharmaceutical inventions between 2005 and 2011, more than 85% were owned by foreign companies in India, with US holding 20-30%  share of the patents.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Noting that the provisions of the Compulsory License enshrined in the India Patent Act are in accordance with the provisions of the TRIPs Agreement and the Paris Convention, she had said that through such licensing mechanisms, all governments balance the rights of the patent holder.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Since its inception, Compulsory Licensing has been an integral part of the patent regime of different countries. Globally, 15 different countries, developed and developing alike, have issued more than 35 compulsory licenses. India has issued only one Compulsory License,&amp;quot; Rao said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
However, Rao&#039;s letter has failed to convince the US pharma industry who continues to push the Obama Administration on India&#039;s policies related to the intellectual property regime.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;India&#039;s protectionist and discriminatory policies which exploit U S IP to benefit their own industry requires an equally bold response.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
It is important that we view these actions for what they are, industrialist policies to benefit the competitiveness of India&#039;s own domestic industry,&amp;quot; Roy Waldron, Chief Intellectual Property Officer with Pfizer, told lawmakers last week.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;India&#039;s actions to undermine the incentives needed to make investment to develop new medicines, a hostile environment to IP will have a devastating impact on R&amp;amp;D investment in both the US and India and cause significant harm for US jobs and economic growth,&amp;quot; he said.
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Business Standard, 2 July, 2013, http://www.business-standard.com/article/economy-policy/ip-environment-deteriorating-in-india-us-pharma-industry-113070200127_1.html&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;ip-environment-deteriorating-in-india-us-pharma-industry-21760&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 21760,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 21613
$metaTitle = &#039;LATEST NEWS UPDATES | IP environment deteriorating in India: US pharma industry&#039;
$metaKeywords = &#039;medicines,patents,generic drugs,Health&#039;
$metaDesc = &#039;
-PTI



India however maintained that the India Patent Act was in accordance with the TRIPS Agreement &amp;amp; the Paris Convention


The US pharma industry has expressed concern over deteriorating intellectual property environment in India, alleging that patent rights in the country are...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-PTI&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;India however maintained that the India Patent Act was in accordance with the TRIPS Agreement &amp;amp; the Paris Convention&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The US pharma industry has expressed concern over deteriorating intellectual property environment in India, alleging that patent rights in the country are unreasonably denied.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;PhRMA remains concerned about the deteriorating intellectual property environment in India,&amp;quot; Mark Grayson, PhRMA spokesman told PTI.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The remarks by PhRMA or Pharmaceutical Research and Manufacturers of America, representing America&#039;s leading biopharmaceutical researchers and biotechnology companies, comes days after the India&#039;s Ambassador to the US, Nirupama Rao, wrote to US lawmakers and a Congressional committee held a hearing on the issue.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;We have shared our views about the importance of promoting a policy environment that supports continued research and development of new medicines with Ambassador Rao and other members of the Indian Government,&amp;quot; Grayson said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In a letter to US lawmakers last month, Rao had defended India&#039;s IP policy arguing that India has a well-settled, stable and robust intellectual property regime.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;The three main pillars of this regime are comprehensive laws, detailed rules to back them up, and strong enforcement mechanisms, including for dispute resolution,&amp;quot; she had said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Rao had said of all patents granted for pharmaceutical inventions between 2005 and 2011, more than 85% were owned by foreign companies in India, with US holding 20-30%  share of the patents.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Noting that the provisions of the Compulsory License enshrined in the India Patent Act are in accordance with the provisions of the TRIPs Agreement and the Paris Convention, she had said that through such licensing mechanisms, all governments balance the rights of the patent holder.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Since its inception, Compulsory Licensing has been an integral part of the patent regime of different countries. Globally, 15 different countries, developed and developing alike, have issued more than 35 compulsory licenses. India has issued only one Compulsory License,&amp;quot; Rao said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;However, Rao&#039;s letter has failed to convince the US pharma industry who continues to push the Obama Administration on India&#039;s policies related to the intellectual property regime.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;India&#039;s protectionist and discriminatory policies which exploit U S IP to benefit their own industry requires an equally bold response.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;It is important that we view these actions for what they are, industrialist policies to benefit the competitiveness of India&#039;s own domestic industry,&amp;quot; Roy Waldron, Chief Intellectual Property Officer with Pfizer, told lawmakers last week.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;India&#039;s actions to undermine the incentives needed to make investment to develop new medicines, a hostile environment to IP will have a devastating impact on R&amp;amp;D investment in both the US and India and cause significant harm for US jobs and economic growth,&amp;quot; he said.&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/ip-environment-deteriorating-in-india-us-pharma-industry-21760.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | IP environment deteriorating in India: US pharma industry | Im4change.org</title>
    <meta name="description" content="
-PTI



India however maintained that the India Patent Act was in accordance with the TRIPS Agreement &amp; the Paris Convention


The US pharma industry has expressed concern over deteriorating intellectual property environment in India, alleging that patent rights in the country are..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>IP environment deteriorating in India: US pharma industry</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-PTI</div><p align="justify"><br /><em>India however maintained that the India Patent Act was in accordance with the TRIPS Agreement &amp; the Paris Convention</em></p><p align="justify">The US pharma industry has expressed concern over deteriorating intellectual property environment in India, alleging that patent rights in the country are unreasonably denied.</p><p align="justify">&quot;PhRMA remains concerned about the deteriorating intellectual property environment in India,&quot; Mark Grayson, PhRMA spokesman told PTI.</p><p align="justify">The remarks by PhRMA or Pharmaceutical Research and Manufacturers of America, representing America's leading biopharmaceutical researchers and biotechnology companies, comes days after the India's Ambassador to the US, Nirupama Rao, wrote to US lawmakers and a Congressional committee held a hearing on the issue.</p><p align="justify">&quot;We have shared our views about the importance of promoting a policy environment that supports continued research and development of new medicines with Ambassador Rao and other members of the Indian Government,&quot; Grayson said.</p><p align="justify">In a letter to US lawmakers last month, Rao had defended India's IP policy arguing that India has a well-settled, stable and robust intellectual property regime.</p><p align="justify">&quot;The three main pillars of this regime are comprehensive laws, detailed rules to back them up, and strong enforcement mechanisms, including for dispute resolution,&quot; she had said.</p><p align="justify">Rao had said of all patents granted for pharmaceutical inventions between 2005 and 2011, more than 85% were owned by foreign companies in India, with US holding 20-30%  share of the patents.</p><p align="justify">Noting that the provisions of the Compulsory License enshrined in the India Patent Act are in accordance with the provisions of the TRIPs Agreement and the Paris Convention, she had said that through such licensing mechanisms, all governments balance the rights of the patent holder.</p><p align="justify">&quot;Since its inception, Compulsory Licensing has been an integral part of the patent regime of different countries. Globally, 15 different countries, developed and developing alike, have issued more than 35 compulsory licenses. India has issued only one Compulsory License,&quot; Rao said.</p><p align="justify">However, Rao's letter has failed to convince the US pharma industry who continues to push the Obama Administration on India's policies related to the intellectual property regime.</p><p align="justify">&quot;India's protectionist and discriminatory policies which exploit U S IP to benefit their own industry requires an equally bold response.</p><p align="justify">It is important that we view these actions for what they are, industrialist policies to benefit the competitiveness of India's own domestic industry,&quot; Roy Waldron, Chief Intellectual Property Officer with Pfizer, told lawmakers last week.</p><p align="justify">&quot;India's actions to undermine the incentives needed to make investment to develop new medicines, a hostile environment to IP will have a devastating impact on R&amp;D investment in both the US and India and cause significant harm for US jobs and economic growth,&quot; he said.</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 21613,
		'title' => 'IP environment deteriorating in India: US pharma industry',
		'subheading' => '',
		'description' => '<div align="justify">
-PTI
</div>
<p align="justify">
<br />
<em>India however maintained that the India Patent Act was in accordance with the TRIPS Agreement &amp; the Paris Convention</em>
</p>
<p align="justify">
The US pharma industry has expressed concern over deteriorating intellectual property environment in India, alleging that patent rights in the country are unreasonably denied.
</p>
<p align="justify">
&quot;PhRMA remains concerned about the deteriorating intellectual property environment in India,&quot; Mark Grayson, PhRMA spokesman told PTI.
</p>
<p align="justify">
The remarks by PhRMA or Pharmaceutical Research and Manufacturers of America, representing America's leading biopharmaceutical researchers and biotechnology companies, comes days after the India's Ambassador to the US, Nirupama Rao, wrote to US lawmakers and a Congressional committee held a hearing on the issue.
</p>
<p align="justify">
&quot;We have shared our views about the importance of promoting a policy environment that supports continued research and development of new medicines with Ambassador Rao and other members of the Indian Government,&quot; Grayson said.
</p>
<p align="justify">
In a letter to US lawmakers last month, Rao had defended India's IP policy arguing that India has a well-settled, stable and robust intellectual property regime.
</p>
<p align="justify">
&quot;The three main pillars of this regime are comprehensive laws, detailed rules to back them up, and strong enforcement mechanisms, including for dispute resolution,&quot; she had said.
</p>
<p align="justify">
Rao had said of all patents granted for pharmaceutical inventions between 2005 and 2011, more than 85% were owned by foreign companies in India, with US holding 20-30%  share of the patents.
</p>
<p align="justify">
Noting that the provisions of the Compulsory License enshrined in the India Patent Act are in accordance with the provisions of the TRIPs Agreement and the Paris Convention, she had said that through such licensing mechanisms, all governments balance the rights of the patent holder.
</p>
<p align="justify">
&quot;Since its inception, Compulsory Licensing has been an integral part of the patent regime of different countries. Globally, 15 different countries, developed and developing alike, have issued more than 35 compulsory licenses. India has issued only one Compulsory License,&quot; Rao said.
</p>
<p align="justify">
However, Rao's letter has failed to convince the US pharma industry who continues to push the Obama Administration on India's policies related to the intellectual property regime.
</p>
<p align="justify">
&quot;India's protectionist and discriminatory policies which exploit U S IP to benefit their own industry requires an equally bold response.
</p>
<p align="justify">
It is important that we view these actions for what they are, industrialist policies to benefit the competitiveness of India's own domestic industry,&quot; Roy Waldron, Chief Intellectual Property Officer with Pfizer, told lawmakers last week.
</p>
<p align="justify">
&quot;India's actions to undermine the incentives needed to make investment to develop new medicines, a hostile environment to IP will have a devastating impact on R&amp;D investment in both the US and India and cause significant harm for US jobs and economic growth,&quot; he said.
</p>',
		'credit_writer' => 'The Business Standard, 2 July, 2013, http://www.business-standard.com/article/economy-policy/ip-environment-deteriorating-in-india-us-pharma-industry-113070200127_1.html',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'ip-environment-deteriorating-in-india-us-pharma-industry-21760',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 21760,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 21613,
	'metaTitle' => 'LATEST NEWS UPDATES | IP environment deteriorating in India: US pharma industry',
	'metaKeywords' => 'medicines,patents,generic drugs,Health',
	'metaDesc' => '
-PTI



India however maintained that the India Patent Act was in accordance with the TRIPS Agreement &amp; the Paris Convention


The US pharma industry has expressed concern over deteriorating intellectual property environment in India, alleging that patent rights in the country are...',
	'disp' => '<div align="justify">-PTI</div><p align="justify"><br /><em>India however maintained that the India Patent Act was in accordance with the TRIPS Agreement &amp; the Paris Convention</em></p><p align="justify">The US pharma industry has expressed concern over deteriorating intellectual property environment in India, alleging that patent rights in the country are unreasonably denied.</p><p align="justify">&quot;PhRMA remains concerned about the deteriorating intellectual property environment in India,&quot; Mark Grayson, PhRMA spokesman told PTI.</p><p align="justify">The remarks by PhRMA or Pharmaceutical Research and Manufacturers of America, representing America's leading biopharmaceutical researchers and biotechnology companies, comes days after the India's Ambassador to the US, Nirupama Rao, wrote to US lawmakers and a Congressional committee held a hearing on the issue.</p><p align="justify">&quot;We have shared our views about the importance of promoting a policy environment that supports continued research and development of new medicines with Ambassador Rao and other members of the Indian Government,&quot; Grayson said.</p><p align="justify">In a letter to US lawmakers last month, Rao had defended India's IP policy arguing that India has a well-settled, stable and robust intellectual property regime.</p><p align="justify">&quot;The three main pillars of this regime are comprehensive laws, detailed rules to back them up, and strong enforcement mechanisms, including for dispute resolution,&quot; she had said.</p><p align="justify">Rao had said of all patents granted for pharmaceutical inventions between 2005 and 2011, more than 85% were owned by foreign companies in India, with US holding 20-30%  share of the patents.</p><p align="justify">Noting that the provisions of the Compulsory License enshrined in the India Patent Act are in accordance with the provisions of the TRIPs Agreement and the Paris Convention, she had said that through such licensing mechanisms, all governments balance the rights of the patent holder.</p><p align="justify">&quot;Since its inception, Compulsory Licensing has been an integral part of the patent regime of different countries. Globally, 15 different countries, developed and developing alike, have issued more than 35 compulsory licenses. India has issued only one Compulsory License,&quot; Rao said.</p><p align="justify">However, Rao's letter has failed to convince the US pharma industry who continues to push the Obama Administration on India's policies related to the intellectual property regime.</p><p align="justify">&quot;India's protectionist and discriminatory policies which exploit U S IP to benefit their own industry requires an equally bold response.</p><p align="justify">It is important that we view these actions for what they are, industrialist policies to benefit the competitiveness of India's own domestic industry,&quot; Roy Waldron, Chief Intellectual Property Officer with Pfizer, told lawmakers last week.</p><p align="justify">&quot;India's actions to undermine the incentives needed to make investment to develop new medicines, a hostile environment to IP will have a devastating impact on R&amp;D investment in both the US and India and cause significant harm for US jobs and economic growth,&quot; he said.</p>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 21613,
	'title' => 'IP environment deteriorating in India: US pharma industry',
	'subheading' => '',
	'description' => '<div align="justify">
-PTI
</div>
<p align="justify">
<br />
<em>India however maintained that the India Patent Act was in accordance with the TRIPS Agreement &amp; the Paris Convention</em>
</p>
<p align="justify">
The US pharma industry has expressed concern over deteriorating intellectual property environment in India, alleging that patent rights in the country are unreasonably denied.
</p>
<p align="justify">
&quot;PhRMA remains concerned about the deteriorating intellectual property environment in India,&quot; Mark Grayson, PhRMA spokesman told PTI.
</p>
<p align="justify">
The remarks by PhRMA or Pharmaceutical Research and Manufacturers of America, representing America's leading biopharmaceutical researchers and biotechnology companies, comes days after the India's Ambassador to the US, Nirupama Rao, wrote to US lawmakers and a Congressional committee held a hearing on the issue.
</p>
<p align="justify">
&quot;We have shared our views about the importance of promoting a policy environment that supports continued research and development of new medicines with Ambassador Rao and other members of the Indian Government,&quot; Grayson said.
</p>
<p align="justify">
In a letter to US lawmakers last month, Rao had defended India's IP policy arguing that India has a well-settled, stable and robust intellectual property regime.
</p>
<p align="justify">
&quot;The three main pillars of this regime are comprehensive laws, detailed rules to back them up, and strong enforcement mechanisms, including for dispute resolution,&quot; she had said.
</p>
<p align="justify">
Rao had said of all patents granted for pharmaceutical inventions between 2005 and 2011, more than 85% were owned by foreign companies in India, with US holding 20-30%  share of the patents.
</p>
<p align="justify">
Noting that the provisions of the Compulsory License enshrined in the India Patent Act are in accordance with the provisions of the TRIPs Agreement and the Paris Convention, she had said that through such licensing mechanisms, all governments balance the rights of the patent holder.
</p>
<p align="justify">
&quot;Since its inception, Compulsory Licensing has been an integral part of the patent regime of different countries. Globally, 15 different countries, developed and developing alike, have issued more than 35 compulsory licenses. India has issued only one Compulsory License,&quot; Rao said.
</p>
<p align="justify">
However, Rao's letter has failed to convince the US pharma industry who continues to push the Obama Administration on India's policies related to the intellectual property regime.
</p>
<p align="justify">
&quot;India's protectionist and discriminatory policies which exploit U S IP to benefit their own industry requires an equally bold response.
</p>
<p align="justify">
It is important that we view these actions for what they are, industrialist policies to benefit the competitiveness of India's own domestic industry,&quot; Roy Waldron, Chief Intellectual Property Officer with Pfizer, told lawmakers last week.
</p>
<p align="justify">
&quot;India's actions to undermine the incentives needed to make investment to develop new medicines, a hostile environment to IP will have a devastating impact on R&amp;D investment in both the US and India and cause significant harm for US jobs and economic growth,&quot; he said.
</p>',
	'credit_writer' => 'The Business Standard, 2 July, 2013, http://www.business-standard.com/article/economy-policy/ip-environment-deteriorating-in-india-us-pharma-industry-113070200127_1.html',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'ip-environment-deteriorating-in-india-us-pharma-industry-21760',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 21760,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {},
		(int) 2 => object(Cake\ORM\Entity) {},
		(int) 3 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 21613
$metaTitle = 'LATEST NEWS UPDATES | IP environment deteriorating in India: US pharma industry'
$metaKeywords = 'medicines,patents,generic drugs,Health'
$metaDesc = '
-PTI



India however maintained that the India Patent Act was in accordance with the TRIPS Agreement &amp; the Paris Convention


The US pharma industry has expressed concern over deteriorating intellectual property environment in India, alleging that patent rights in the country are...'
$disp = '<div align="justify">-PTI</div><p align="justify"><br /><em>India however maintained that the India Patent Act was in accordance with the TRIPS Agreement &amp; the Paris Convention</em></p><p align="justify">The US pharma industry has expressed concern over deteriorating intellectual property environment in India, alleging that patent rights in the country are unreasonably denied.</p><p align="justify">&quot;PhRMA remains concerned about the deteriorating intellectual property environment in India,&quot; Mark Grayson, PhRMA spokesman told PTI.</p><p align="justify">The remarks by PhRMA or Pharmaceutical Research and Manufacturers of America, representing America's leading biopharmaceutical researchers and biotechnology companies, comes days after the India's Ambassador to the US, Nirupama Rao, wrote to US lawmakers and a Congressional committee held a hearing on the issue.</p><p align="justify">&quot;We have shared our views about the importance of promoting a policy environment that supports continued research and development of new medicines with Ambassador Rao and other members of the Indian Government,&quot; Grayson said.</p><p align="justify">In a letter to US lawmakers last month, Rao had defended India's IP policy arguing that India has a well-settled, stable and robust intellectual property regime.</p><p align="justify">&quot;The three main pillars of this regime are comprehensive laws, detailed rules to back them up, and strong enforcement mechanisms, including for dispute resolution,&quot; she had said.</p><p align="justify">Rao had said of all patents granted for pharmaceutical inventions between 2005 and 2011, more than 85% were owned by foreign companies in India, with US holding 20-30%  share of the patents.</p><p align="justify">Noting that the provisions of the Compulsory License enshrined in the India Patent Act are in accordance with the provisions of the TRIPs Agreement and the Paris Convention, she had said that through such licensing mechanisms, all governments balance the rights of the patent holder.</p><p align="justify">&quot;Since its inception, Compulsory Licensing has been an integral part of the patent regime of different countries. Globally, 15 different countries, developed and developing alike, have issued more than 35 compulsory licenses. India has issued only one Compulsory License,&quot; Rao said.</p><p align="justify">However, Rao's letter has failed to convince the US pharma industry who continues to push the Obama Administration on India's policies related to the intellectual property regime.</p><p align="justify">&quot;India's protectionist and discriminatory policies which exploit U S IP to benefit their own industry requires an equally bold response.</p><p align="justify">It is important that we view these actions for what they are, industrialist policies to benefit the competitiveness of India's own domestic industry,&quot; Roy Waldron, Chief Intellectual Property Officer with Pfizer, told lawmakers last week.</p><p align="justify">&quot;India's actions to undermine the incentives needed to make investment to develop new medicines, a hostile environment to IP will have a devastating impact on R&amp;D investment in both the US and India and cause significant harm for US jobs and economic growth,&quot; he said.</p>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

IP environment deteriorating in India: US pharma industry

-PTI India however maintained that the India Patent Act was in accordance with the TRIPS Agreement & the Paris Convention The US pharma industry has expressed concern over deteriorating intellectual property environment in India, alleging that patent rights in the country are unreasonably denied. "PhRMA remains concerned about the deteriorating intellectual property environment in India," Mark Grayson, PhRMA spokesman told PTI. The remarks by PhRMA or Pharmaceutical Research and Manufacturers of America, representing America's leading biopharmaceutical researchers and biotechnology companies, comes days after the India's Ambassador to the US, Nirupama Rao, wrote to US lawmakers and a Congressional committee held a hearing on the issue. "We have shared our views about the importance of promoting a policy environment that supports continued research and development of new medicines with Ambassador Rao and other members of the Indian Government," Grayson said. In a letter to US lawmakers last month, Rao had defended India's IP policy arguing that India has a well-settled, stable and robust intellectual property regime. "The three main pillars of this regime are comprehensive laws, detailed rules to back them up, and strong enforcement mechanisms, including for dispute resolution," she had said. Rao had said of all patents granted for pharmaceutical inventions between 2005 and 2011, more than 85% were owned by foreign companies in India, with US holding 20-30% share of the patents. Noting that the provisions of the Compulsory License enshrined in the India Patent Act are in accordance with the provisions of the TRIPs Agreement and the Paris Convention, she had said that through such licensing mechanisms, all governments balance the rights of the patent holder. "Since its inception, Compulsory Licensing has been an integral part of the patent regime of different countries. Globally, 15 different countries, developed and developing alike, have issued more than 35 compulsory licenses. India has issued only one Compulsory License," Rao said. However, Rao's letter has failed to convince the US pharma industry who continues to push the Obama Administration on India's policies related to the intellectual property regime. "India's protectionist and discriminatory policies which exploit U S IP to benefit their own industry requires an equally bold response. It is important that we view these actions for what they are, industrialist policies to benefit the competitiveness of India's own domestic industry," Roy Waldron, Chief Intellectual Property Officer with Pfizer, told lawmakers last week. "India's actions to undermine the incentives needed to make investment to develop new medicines, a hostile environment to IP will have a devastating impact on R&D investment in both the US and India and cause significant harm for US jobs and economic growth," he said.